Replies to post #23424 on CytoSorbents Corporation (CTSO)

[techxen]

Regarding this MDMA case and Germany, I noticed also that most of the physicians are on faculty at the University of Freiburg where one of CTSO Covid-19 trials is being run (CYCOV trial). There is a lot going on at the University of Freiburg with regards to Cytosorb.

With regards to commercialization, once the company can establish a "beachhead" here in the US for their first approval (cardiac or ticagrelor removal) and start building out that business, there is so much in the pipeline that is yet to be commercialized. Most of these pipeline products have been forgotten due to the focus on critical care/sepsis, cardiac surgery and Covid-19, but each addresses a multi-million or billion dollar market:

CytoSorb XL – an intended next generation successor to CytoSorb currently in advanced pre-clinical testing designed to reduce a broad range of cytokines and inflammatory mediators, including lipopolysaccharide (LPS) endotoxin, from blood.

HemoDefend – a development-stage blood purification technology designed to remove non-infectious contaminants in blood transfusion
products, with the goal of reducing transfusion reactions and improving the quality and safety of blood. With the support of NHLBI, the plan is to file an IDE application for a U.S. pivotal trial designed to support U.S. FDA approval sometime this year.

K+ontrol – a development-stage blood purification technology designed to reduce excessive levels of potassium in the blood that can be fatal in severe hyperkalemia.

ContrastSorb – a development-stage extracorporeal hemoperfusion cartridge designed to remove IV contrast from the blood of high risk
patients undergoing CT imaging with contrast, or interventional radiology procedures such as cardiac catheterization. The goal of
ContrastSorb is to prevent contrast-induced nephropathy.

DrugSorb – a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood (e.g., drug overdose, high dose regional chemotherapy).

BetaSorb – a development-stage extracorporeal hemoperfusion cartridge designed to remove mid-molecular weight toxins, such as b2-microglobulin, that standard high-flux dialysis cannot remove effectively. The goal of BetaSorb is to improve the efficacy of dialysis or hemofiltration.